Abstract
After prolonged androgen deprivation therapy, a subset of castrate-resistant prostate cancer patients will develop neuroendocrine prostate cancer (NEPC) associated with resistance to further hormonal therapy and frequent visceral metastases. Imaging the presence of somatostatin receptors on the cancer cell surface may provide a readily available, noninvasive means to distinguish adenocarcinoma from NEPC. This distinction is important for therapeutic decision making and may open the door for developing novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer. We describe a case of NEPC successfully imaged using 111In-labeled octreotide.
Original language | English (US) |
---|---|
Pages (from-to) | 540-541 |
Number of pages | 2 |
Journal | Clinical nuclear medicine |
Volume | 40 |
Issue number | 6 |
DOIs | |
State | Published - Jun 25 2015 |
Bibliographical note
Publisher Copyright:© 2015 Wolters Kluwer Health, Inc. All rights reserved.
Keywords
- FDG
- neuroendocrine
- octreotide
- prostate cancer
- somatostatin